AstraZeneca says Etcamah approved in US for HR+ breast cancer
AstraZeneca said Etcamah was approved in the US for HR+ breast cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AstraZeneca’s Etcamah approved in the US for HR+ breast cancer
AstraZeneca PLC said Etcamah in combination with a CDK4/6 inhibitor has been approved in the US for 1st-line advanced HR-positive breast cancer. Approval is based on SERENA-6 Phase III trial results.
AstraZeneca’s ETCAMAH (camizestrant) combo gains US 1st-line HR+ breast cancer approval
AstraZeneca says ETCAMAH (camizestrant) with a CDK4/6 inhibitor—abemaciclib, palbociclib or ribociclib—has been approved in the US for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.